Effect of combination therapy on joint destruction in rheumatoid arthritis: A network meta-analysis of randomized controlled trials

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Graudal, Niels ^a   Hubeck Graudal, Thorbjørn ^b   Tarp, Simon ^c   Christensen, Robin ^c,d   Jürgens, Gesche ^c  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CHLOROQUINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; OCRELIZUMAB; PENICILLAMINE; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ARTICLE; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HUMAN; JOINT DESTRUCTION; LOW DRUG DOSE; META ANALYSIS; OUTCOME ASSESSMENT; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM; ARTHRITIS, RHEUMATOID; DRUG COMBINATION; DRUG EFFECTS; JOINT; PATHOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; JOINTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907225912     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106408     Document Type: Article

References (70)

1. Graudal N, Jürgens G (2010) Similar effects of disease-modifying antirheumatic drugs, glucocorticoids and biologics on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo or drug controlled studies including 112 comparisons. Arthritis Rheum 62: 2852-2863.
2. Estellat C, Ravaud P (2012) Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch Intern Med 172: 237-44.
3. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52: 3381-90.
4. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, et al. (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146: 406-15.
5. Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, et al. (2012) Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379: 1712-20.
6. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, et al. (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 64: 2824-35.
7. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, et al. (2013) Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369: 307-18.
8. Caldwell DM, Ades AE, Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331: 897-900.
9. Nixon RM, Bansback N, Brennan A (2007) Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med 26: 1237-54.
10. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, et al. (2009) A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 181: 787-96.
11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.
12. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, et al. (2009) Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 338: b1147
13. The Nordic Cochrane Centre, Higgins JP, Green S, editors (2009) Cochrane handbook for systematic reviews of interventions version 5.0.1, section 7.7.3. The Cochrane Collaboration. Available: www.cochrane-handbook.org.
14. Walter SD, Yao X (2009) Effect sizes can be calculated for studies reporting ranges for outcome variables in systematic reviews. J Clin Epidemiol 60: 849-52.
15. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, et al. (2011) Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health; 14: 417-28.
16. Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50: 683-91.
17. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, et al. (1999) Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58: 220-225.
18. Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, et al. (2003) Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology 42: 1545-49.
19. Sarzi-Puttini P, D'Ingianna E, Fumagalli M, Scarpellini M, Fiorini T, et al. (2005) An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int 25: 15-22.
20. Scott DL, Dawes PT, Tunn E, Fowler PD, Shadforth MF, et al. (1989) Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study. Br J Rheumatol 28: 128-33.
21. Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, et al. (2004) Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 63: 797-803.
22. Choy EH, Kingsley GH, Khoshaba B, Pipitone N, Scott DL (2005) Intramuscular Methylprednisolone Study. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 64: 1288-93
23. Hansen M, Podenphant J, Florescu A, Stoltenberg M, Borch A, et al. (1999) A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis 58: 713-18.
24. Kirwan JR, The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 333: 142-46.
25. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, et al. (2005) Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 52: 3360-3370.
26. Van Gestel AM, Laan RF, Haagsma CJ, Van de Putte LB, van Riel PL (1995) Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Br J Rheumatol 34: 347-51.
27. Wassenberg S, Rau R, Steinfeld P, Zeidler H (2005) Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 52: 3371-80.
28. Choy EH, Smith CN, Farewell V, Walker D, Hassell A, et al. (2008) Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 67: 656-63.
29. Calgüneri M, Pay S, Caliskaner Z, Apras S, Kiraz S, et al. (1999) Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 17: 699-704.
30. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, et al. (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364: 263-69.
31. Möttönen T, Hannonen P, Leirisalo-Repo M, NissiläM, Kautiainen H, et al. (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353: 1568-73.
32. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, et al. (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350: 309-18.
33. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, et al. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 363: 675-81.
34. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, et al. (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372: 375-82.
35. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594-602.
36. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, et al. (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50: 3432-43.
37. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, et al. (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26-37.
38. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50: 1400-1411.
39. Keystone E, van der Heijde D, Mason D, Landewé R, Vollenhoven RV, et al. (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-twoweek phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58: 3319-29.
40. Smolen JS, Landewé RB, Mease PJ, Brzezicki J, Mason D, et al. (2009) Efficacy and Safety of Certolizumab Pegol plus Methotrexate in Active Rheumatoid Arthritis: The RAPID 2 Study. Ann Rheum Dis 68: 797-804.
41. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, et al. (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144: 865-76.
42. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, et al. (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68: 1870-7.
43. Keystone EC, Emery P, Peterfy CG, Tak PP, Cohen S, et al. (2009) Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 68: 216-221.
44. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, et al. (2005) Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol 15: 323-8.
45. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, et al. (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70: 39-46.
46. Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, et al. (2011) The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis: Results of randomized controlled studies on Golimimab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 63: 1200-1210.
47. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, et al. (2011) Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 63: 609-621.
48. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, et al. (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156: 329-39.
49. Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, et al. (2012) Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis 71: 817-24.
50. Rigby W, Tony HP, Oelke K, Combe B, Laster A, et al. (2012) Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, doubleblind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 64: 350-9.
51. Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, et al. (2012) Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight- week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 64: 360-70.
52. Stohl W, Gomez-Reino J, Olech E, Dudler J, Fleischmann RM, et al. (2012) Safety and efficacy of ocrelizumab in combination with methotrexate in MTXnaive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis 71: 1289-96.
53. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, et al. (2013) Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 72: 64-71.
54. Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, et al. (2010) Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39: 425-41.
55. Devine EB, Alfonso-Cristancho R, Sullivan SD (2011). Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy 31: 39-51.
56. Launois R, Avouac B, Berenbaum F, Blin O, Bru I, et al. (2011) Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol 38: 835-45.
57. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, et al. (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional diseasemodifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a metaanalysis. Ann Rheum Dis 70: 266-71.
58. Schmitz S, Adams R, Walsh CD, Barry M, Fitzgerald O (2012) A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis 71: 225-30.
59. Turkstra E, Ng SK, Scuffham PA (2011) A mixed treatment comparison of the short term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin 27: 1885-97.
60. Rahman MU, Buchanan J, Doyle MK, Hsia EC, Gathany T, et al. (2011) Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis 70: 1631-40.
61. Brower AC (1990) Use of the radiograph to measure the course of rheumatoid arthritis. The gold standard versus fool's gold. Arthritis Rheum 33: 316-24.
62. Graudal NA, Jurik AG, de Carvalho A, Graudal HK (1998) Radiographic progression in rheumatoid arthritis: a long-term prospective study of 109 patients. Arthritis Rheum 41: 1470-80.
63. Graudal N, Tarp U, Jurik AG, Galloe AM, Garred P, et al. (2000) Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentationrate, and hemoglobin: long-term course and association to radiographic progression. J Rheumatol 27: 47-57.
64. Graudal N (2004) The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins. Scand J Rheumatol 33 (Suppl 118): 1-37.
65. Donahue KE, Jonas DE, Hansen RA, Roubey R, Jonas B, et al. (2012) Drug Therapy for Rheumatoid Arthritis in Adults: An Update [Internet]. Agency for Healthcare Research and Quality (US). Report No.: 12-EHC025-EF. AHRQ Comparative Effectiveness Reviews.
66. Ma MH, Kingsley GH, Scott DL (2010) A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford). 49: 91-8.
67. Scott DL (2012) Biologic based therapy for the treatment of rheumatoid arthritis. CPT 91: 30-43.
68. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69: 964-75.
69. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, et al. (2012) 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care Res 64: 625-639.
70. Pearson SD (2012) Placebo-controlled trials, ethics, and the goals of comparative effectiveness research: comment on "lack of head-to-head trials and fair control arms". Arch Intern Med 172: 244-5.